Table 2.

Inclusion criteria for the discovery study

Warfarin arm	Clopidogrel arm	NOAC arm
Both new starts and currently on warfarin	Clopidogrel 75 mg daily	Taking 15 mg/day of rivaroxaban (Xarelto) or taking 5 mg/day of apixaban (Eliquis) or taking 30 mg/day of edoxaban (Savaysa, Lixiana)
Expected to remain on warfarin for ≥ 3 months	Has been on treatment for at least 14 days Expected to remain on treatment for ≥ 30 days	Has been on treatment for at least 3 days Expected to remain on standard daily dose for ≥ 30 days
Primary indication (at least one): venous thromboembolism, atrial fibrillation, mechanical valve replacement	Primary indication (at least one): history of myocardial infarction, coronary stent placement (drug‐eluting and nondrug‐eluting stents), history of stroke, aspirin intolerance, including hypersensitivity to aspirin or aspirin resistance	Primary indications (at least one): nonvalvular atrial fibrillation, venous thromboembolism treatment, venous thromboembolism prophylaxis

NOAC, novel oral anticoagulant.

Self‐described as African American.

Age > 18 years.

Starting or on treatment with the selected agents.

Speak and understand English.